Chiara Braconi

List of Publications by Citations

Source: https://exaly.com/author-pdf/9496104/chiara-braconi-publications-by-citations.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

65 papers	4,966 citations	29 h-index	70 g-index
75 ext. papers	6,335 ext. citations	8.9 avg, IF	5.28 L-index

#	Paper	IF	Citations
65	Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. *Science*, **2018**, 359, 920-926	33.3	712
64	Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. *Lancet Oncology, The*, **2012**, 13, 265-74	21.7	601
63	Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. *Hepatology*, **2011**, 54, 1237-48	11.2	417
62	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. *Nature Reviews Gastroenterology and Hepatology*, **2020**, 17, 557-588	24.2	355
61	MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 21098-103	11.5	295
60	MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. *Hepatology*, **2010**, 51, 881-90	11.2	285
59	Modulation of mismatch repair and genomic stability by miR-155. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 6982-7	11.5	267
58	MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. *Cancer Cell*, **2014**, 25, 469-83	24.3	235
57	Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 786-91	11.5	186
56	Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. *Journal of Clinical Oncology*, **2016**, 34, 2721-7	2.2	144
55	Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. *Cancer Discovery*, **2018**, 8, 1270-1285	24.4	130
54	KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. *Journal of Clinical Oncology* , **2015**, 33, 634-42	2.2	104
53	The role of microRNAs in human liver cancers. *Seminars in Oncology*, **2011**, 38, 752-63	5.5	98
52	Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes. *Clinical Cancer Research*, **2010**, 16, 957-66	12.9	97
51	MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. *Gastroenterology*, **2018**, 154, 1066-1079.e5	13.3	61
50	Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. *Gut*, **2017**, 66, 1268-1277	19.2	58
49	Cholangiocarcinoma: new insights into disease pathogenesis and biology. *Infectious Disease Clinics of North America*, **2010**, 24, 871-84, vii	6.5	51

48	Hepatic miR-29ab1 expression modulates chronic hepatic injury. *Journal of Cellular and Molecular Medicine*, **2012**, 16, 2647-54	5.6	46
47	Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. *Gut*, **2018**, 67, 1484-1492	19.2	45
46	Noncoding RNAs as novel biomarkers in pancreatic cancer: what do we know?. *Future Oncology*, **2017**, 13, 443-453	3.6	44
45	KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. *Scientific Reports*, **2018**, 8, 1445	4.9	43
44	Characterisation of the immune-related transcriptome in resected biliary tract cancers. *European Journal of Cancer*, **2017**, 86, 158-165	7.5	34
43	Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. *Hpb*, **2017**, 19, 741-748	3.8	33
42	Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma. *Oncotarget*, **2016**, 7, 31361-71	3.3	33
41	Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells. *Liver International*, **2009**, 29, 670-7	7.9	32
40	Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids. *Cell Stem Cell*, **2021**, 28, 816-832	18	32
39	miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial. *Oncotarget*, **2016**, 7, 12672-81	3.3	32
38	Transcribed ultraconserved noncoding RNAs (T-UCR) are involved in Barrett's esophagus carcinogenesis. *Oncotarget*, **2014**, 5, 7162-71	3.3	31
37	Non-Coding RNAs in Primary Liver Cancer. *Frontiers in Medicine*, **2015**, 2, 36	4.9	29
36	Candidate therapeutic agents for hepatocellular cancer can be identified from phenotype-associated gene expression signatures. *Cancer*, **2009**, 115, 3738-48	6.4	29
35	Non-coding RNAs as therapeutic targets in hepatocellular cancer. *Current Cancer Drug Targets*, **2012**, 12, 1073-80	2.8	26
34	Noncoding RNA in Cholangiocarcinoma. *Seminars in Liver Disease*, **2019**, 39, 13-25	7.3	26
33	Targeting the IL-6 dependent phenotype can identify novel therapies for cholangiocarcinoma. *PLoS ONE*, **2010**, 5, e15195	3.7	25
32	miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial. *Clinical Cancer Research*, **2019**, 25, 3830-3838	12.9	23
31	Current and novel therapeutic opportunities for systemic therapy in biliary cancer. *British Journal of Cancer*, **2020**, 123, 1047-1059	8.7	23

30	Emerging molecular targets and therapy for cholangiocarcinoma. *World Journal of Gastrointestinal Oncology*, **2017**, 9, 268-280	3.4	22
29	Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells. *Hepatology*, **2020**, 72, 982-996	11.2	21
28	MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma. *British Journal of Cancer*, **2016**, 115, 1343-1350	8.7	20
27	Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?. *Liver International*, **2019**, 39 Suppl 1, 32-42	7.9	13
26	Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. *Carcinogenesis*, **2016**, 37, 852-7	4.6	13
25	The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy. *European Journal of Cancer*, **2019**, 117, 84-90	7.5	13
24	Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System. *Hepatology*, **2021**, 73, 2311-2325	11.2	13
23	MiR-21 up-regulation in ampullary adenocarcinoma and its pre-invasive lesions. *Pathology Research and Practice*, **2018**, 214, 835-839	3.4	12
22	Biology and Clinical Application of Regulatory RNAs in Hepatocellular Carcinoma. *Hepatology*, **2021**, 73 Suppl 1, 38-48	11.2	12
21	EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers. *Gut*, **2021**, 70, 1632-1641	19.2	11
20	Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.. *Journal of Hepatology*, **2021**,	13.4	10
19	miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis. *Translational Oncology*, **2019**, 12, 282-291	4.9	10
18	Cholangiocarcinoma Disease Modelling Through Patients Derived Organoids. *Cells*, **2020**, 9,	7.9	8
17	Patient-Derived Organoids as a Model for Cancer Drug Discovery. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	7
16	Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience. *Clinical Colorectal Cancer*, **2019**, 18, 64-71.e1	3.8	5
15	Pathogenetic Role and Clinical Implications of Regulatory RNAs in Biliary Tract Cancer. *Cancers*, **2020**, 13,	6.6	4
14	Oligometastatic gastric cancer: An emerging clinical entity with distinct therapeutic implications. *European Journal of Surgical Oncology*, **2019**, 45, 1479-1482	3.6	4
13	MIR21-induced loss of junctional adhesion molecule A promotes activation of oncogenic pathways, progression and metastasis in colorectal cancer. *Cell Death and Differentiation*, **2021**, 28, 2970-2982	12.7	3

List of Publications

12	Anti-miR-135b in colon cancer treatment: Results from a preclinical study.. *Journal of Clinical Oncology*, **2012**, 30, 457-457	2.2	2
11	Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA Registry. *Cancers*, **2022**, 14, 2389	6.6	2
10	Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2006**, 29, 380-4	2.7	1
9	Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. *Nature Communications*, **2021**, 12, 6738	17.4	1
8	Diagnostic accuracy and safety of coaxial core-needle biopsy (CNB) system in Oncology patients treated in a specialist cancer centre with prospective validation within clinical trial data		1
7	Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data. *Frontiers in Oncology*, **2020**, 10, 1634	5.3	1
6	MicroRNAs link inflammation and primary biliary cholangitis. *Non-coding RNA Investigation*, **2018**, 2, 29-29	3.6	1
5	REPLY. *Hepatology*, **2021**, 74, 1129-1131	11.2	1
4	Receptor Tyrosine kinase co-amplification and benefit from HER2 inhibitors in Biliary Tract Cancers.. *Journal of Hepatology*, **2022**,	13.4	0
3	REPLY. *Hepatology*, **2021**, 74, 2319-2321	11.2	0
2	Bridging the equity gap in patient education: the biliary tract cancer BABEL project.. *Lancet Oncology, The*, **2022**, 23, 568-570	21.7	0
1	Organoid Models of Cholangiocarcinoma **2021**, 495-508		